H.I.G. WhiteHorse Europe Refinances Astek
30.5.2024 13:00:00 EEST | Business Wire | Press release
H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G."), is pleased to announce that it has co-arranged a new €450 million financing package for Astek (the “Company” or the “Group”).
Founded in 1988 and controlled by its founder Jean-Luc Bernard, Astek is a global player in engineering and technology consulting. Headquartered in Boulogne-Billancourt, France, Astek operates in more than 20 countries with 8400 employees. Led by Julien Gavaldon since 2013, the Group has experienced significant growth as a result of organic activity and ten strategic acquisitions, over the past four years. The Group has developed leading market positions in its key geographies, notably in France, Poland, and Canada, in addition to growing positions in Northern and Western Europe, the Middle East, and Asia.
In 2021, H.I.G. WhiteHorse Europe acted as the sole arranger of a €170 million financing package used to refinance the Group’s existing loans and provide additional capital for growth. Having reached its business goals two years ahead of schedule, Astek is further strengthening its financial resources to support its plans of continued growth through a new senior-secured financing package of €450 million co-arranged by H.I.G. Additionally, Astek has welcomed its long-term investor, Intermediate Capital Group (“ICG”), as a strategic partner. ICG has provided an additional €110 million in equity financing to the Group.
Jean-Luc Bernard, Founder and Chairman of the Supervisory Board of Astek, said:“H.I.G. has been our partner since 2021 and I would like to thank them for their renewed confidence. The trust that has been built with H.I.G. has further strengthened the Group and Astek is now well-positioned for continued growth and profitability.”
Julien Gavaldon, Chief Executive Officer of Astek, said: “Thanks to our partnership with H.I.G., we have had a very successful growth trajectory, reaching our objectives two years ahead of schedule. We are determined to continue growing the Group, with the goal of exceeding 1 billion euros of turnover before 2027. H.I.G.’s renewed confidence in Astek, coupled with our new strategic partnership with ICG, positions us among the global leaders in digital transformation and technology consulting.”
Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said:“Astek is a remarkable company, led by a high-quality management team, and we are grateful for their renewed trust in H.I.G. WhiteHorse Europe. We are excited to continue supporting Jean-Luc Bernard, Julien Gavaldon, and Astek’s 8,400 employees as they embark on this exciting new phase of development.”
Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We deeply appreciate the renewed confidence shown by Jean-Luc Bernard and Julien Gavaldon in H.I.G. WhiteHorse Europe. Over the past years, Astek has achieved remarkable and consistent growth, establishing itself as a prominent global player. Its impressive market share gains, driven by approximately 20% organic growth (significantly exceeding market expansion) and a well-managed buy-and-build strategy, are a testimony to its success. We are delighted to continue supporting Astek as it embarks on this new chapter of development.”
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $62 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
* Based on total capital raised by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530188790/en/
Contact information
Pascal Meysson
Head of H.I.G. WhiteHorse Europe
pmeysson@hig.com
Charles Bourgeois
Managing Director
cbourgeois@hig.com
H.I.G. WhiteHorse Europe
10 Grosvenor Street
2nd Floor
London W1K 4QB
United Kingdom
P +44 (0) 207 318 5700
hig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
